NASDAQ:EYPT - EyePoint Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $17.63
Forecasted Upside: 113.90 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$8.24 As of 07/23/2021 01:00 AM ET

▲ +0.04 (0.49%)

1 month | 3 months | 12 months

Get New EyePoint Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for EYPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYPT

^$17.63

▲ +113.90% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $17.63, with a high forecast of $25.00 and a low forecast of $8.50. The average price target represents a 113.90% upside from the last price of $8.24.

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in EyePoint Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/21/2021	HC Wainwright	Reiterated Rating	Buy	$15.00	Low
7/9/2021	HC Wainwright	Reiterated Rating	Buy	$15.00	Medium
7/2/2021	HC Wainwright	Reiterated Rating	Buy	$15.00	Low
5/26/2021	HC Wainwright	Reiterated Rating	Buy	$15.00	High
5/6/2021	HC Wainwright	Lower Price Target	Buy	$16.00 ➝ $15.00	High
3/1/2021	Cowen	Initiated Coverage	Outperform	$25.00	Low
1/29/2021	HC Wainwright	Reiterated Rating	Buy	$16.00	Medium
1/27/2021	Cantor Fitzgerald	Initiated Coverage	Overweight	$22.00	High
1/12/2021	B. Riley	Boost Price Target	Buy	$5.00 ➝ $8.50	High
10/9/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$20.00	High
8/6/2020	HC Wainwright	Reiterated Rating	Hold		High
4/6/2020	B. Riley	Downgrade	Buy ➝ Neutral	$40.00 ➝ $10.00	High
4/2/2020	HC Wainwright	Reiterated Rating	Hold		High
3/3/2020	HC Wainwright	Reiterated Rating	Hold		Low
2/4/2020	HC Wainwright	Reiterated Rating	Hold		High
1/24/2020	HC Wainwright	Reiterated Rating	Hold		Low
11/11/2019	HC Wainwright	Downgrade	Buy ➝ Neutral		High
11/5/2019	HC Wainwright	Reiterated Rating	Buy	$45.00	Low
11/4/2019	Laidlaw	Initiated Coverage	Buy	$50.00	High
9/25/2019	HC Wainwright	Reiterated Rating	Buy	$45.00	Low
9/24/2019	B. Riley	Lower Price Target	Buy	$57.50 ➝ $40.00	Medium
9/12/2019	Guggenheim	Initiated Coverage	Buy	$40.00	High
7/12/2019	HC Wainwright	Set Price Target	Buy	$50.00	Low
5/9/2019	HC Wainwright	Reiterated Rating	Buy	$45.00	Low
4/2/2019	HC Wainwright	Set Price Target	Buy	$50.00	Low
1/4/2019	HC Wainwright	Set Price Target	Buy	$50.00	Medium
10/16/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00	High
10/1/2018	HC Wainwright	Reiterated Rating	Buy	$45.00	Low
9/13/2018	HC Wainwright	Reiterated Rating	Buy	$27.50	Medium
9/6/2018	HC Wainwright	Set Price Target	Buy	$30.00	Low
8/2/2018	HC Wainwright	Set Price Target	Buy	$30.00	Low
7/27/2018	HC Wainwright	Set Price Target	Buy	$30.00	Low
6/26/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium
5/9/2018	HC Wainwright	Set Price Target	Buy	$30.00	High
4/13/2018	HC Wainwright	Reiterated Rating	Buy	$30.00	Medium
4/2/2018	HC Wainwright	Set Price Target	Buy	$30.00	N/A
3/20/2018	HC Wainwright	Set Price Target	Buy	$50.00	Medium
2/8/2018	HC Wainwright	Set Price Target	Buy	$50.00	High
1/9/2018	HC Wainwright	Reiterated Rating	Buy	$50.00	Low
12/15/2017	HC Wainwright	Set Price Target	Buy	$50.00	High
12/15/2017	B. Riley	Set Price Target	Buy	$50.00	Medium
12/11/2017	Northland Securities	Reiterated Rating	Buy	$100.00	Medium
12/4/2017	B. Riley	Set Price Target	Buy	$50.00	Medium
11/8/2017	HC Wainwright	Reiterated Rating	Buy	$50.00	N/A
11/8/2017	Laidlaw	Initiated Coverage	Buy	$50.00	N/A
10/11/2017	HC Wainwright	Set Price Target	Buy	$50.00	N/A
9/27/2017	HC Wainwright	Reiterated Rating	Buy	$50.00	Low
9/12/2017	HC Wainwright	Reiterated Rating	Buy	$50.00	Medium
7/11/2017	HC Wainwright	Set Price Target	Buy	$50.00	High
6/24/2017	HC Wainwright	Set Price Target	Buy	$80.00	High
6/14/2017	LADENBURG THALM/SH SH	Set Price Target	Buy	$130.00	Medium
6/14/2017	HC Wainwright	Set Price Target	Buy	$80.00	Medium
6/14/2017	Northland Securities	Set Price Target	Buy	$100.00	Medium
6/14/2017	(FBRC)	Reiterated Rating	Buy		High
5/30/2017	HC Wainwright	Reiterated Rating	Buy	$80.00	High
5/30/2017	Rodman & Renshaw	Initiated Coverage	Buy	$80.00	High
5/15/2017	(FBRC)	Reiterated Rating	Outperform	$70.00	Medium
12/6/2016	(FBRC)	Reiterated Rating	Outperform	$70.00	N/A
8/10/2016	(FBRC)	Reiterated Rating	Buy		N/A

(Data available from 7/25/2016 forward)

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $8.24

$8.00

$8.52

50 Day Range

MA: $8.96

$7.51

$9.88

52 Week Range

Now: $8.24

$3.51

$15.06

Volume

105,886 shs

Average Volume

280,890 shs

Market Capitalization

$236.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of EyePoint Pharmaceuticals?

The following Wall Street analysts have issued reports on EyePoint Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, Cowen Inc, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for EYPT.

What is the current price target for EyePoint Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for EyePoint Pharmaceuticals in the last year. Their average twelve-month price target is $17.63, suggesting a possible upside of 113.9%. Cowen Inc has the highest price target set, predicting EYPT will reach $25.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.50 for EyePoint Pharmaceuticals in the next year.
View the latest price targets for EYPT.

What is the current consensus analyst rating for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EYPT will outperform the market and that investors should add to their positions of EyePoint Pharmaceuticals.
View the latest ratings for EYPT.

What other companies compete with EyePoint Pharmaceuticals?

Other companies that are similar to EyePoint Pharmaceuticals include Akoya Biosciences, Codex DNA, Fluidigm, Accelerate Diagnostics, Harvard Bioscience, Talis Biomedical, Precipio, Astrotech, Scientific Industries, HTG Molecular Diagnostics, Pressure BioSciences, BioForce Nanosciences, Arrayit, DiaSys and Orthometrix.

How do I contact EyePoint Pharmaceuticals' investor relations team?

EyePoint Pharmaceuticals' physical mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company's listed phone number is 617-926-5000 and its investor relations email address is [email protected] The official website for EyePoint Pharmaceuticals is eyepointpharma.com.